BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Belopolsky Y, Grinblatt DL, Dunnenberger HM, Sabatini LM, Joseph NE, Fimmel CJ. A Case of Severe, Nilotinib-Induced Liver Injury. ACG Case Rep J 2019;6:e00003. [PMID: 31616712 DOI: 10.14309/crj.0000000000000003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hwang WL, Chen TC, Lin HY, Chang MC, Hsiao PC, Bai LY, Kuo CY, Chen YC, Liu TC, Gau JP, Wang PN, Hwang WS, Kuo MC, Liu CY, Liu YC, Ma MC, Su NW, Wang CC, Wu YY, Yao M, Yeh SP, Cheng HW, Lee YM, Ku FC, Tang JL. NOVEL-1st: an observational study to assess the safety and efficacy of nilotinib in newly diagnosed patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase in Taiwan. Int J Hematol 2022. [PMID: 35212915 DOI: 10.1007/s12185-022-03311-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Wang Z, Wang X, Wang Z, Feng Y, Jia Y, Jiang L, Xia Y, Cao J, Liu Y. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2120165. [PMID: 34292334 DOI: 10.1001/jamanetworkopen.2021.20165] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
3 Kim JS, Han JM, Cho YS, Choi KH, Gwak HS. Machine Learning Approaches to Predict Hepatotoxicity Risk in Patients Receiving Nilotinib. Molecules 2021;26:3300. [PMID: 34072626 DOI: 10.3390/molecules26113300] [Reference Citation Analysis]
4 Nelson RS, Seligson ND, Bottiglieri S, Carballido E, Cueto AD, Imanirad I, Levine R, Parker AS, Swain SM, Tillman EM, Hicks JK. UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation. Cancers (Basel) 2021;13:1566. [PMID: 33805415 DOI: 10.3390/cancers13071566] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
5 Goda AE, Elsisi AE, Sokkar SS, Abdelrazik NM. Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib/rosuvastatin novel combination. Toxicol Appl Pharmacol 2020;404:115185. [PMID: 32771489 DOI: 10.1016/j.taap.2020.115185] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
6 Yang H, Sung PS, Jung ES, Cho S, Bae SH, Kim DW. Nilotinib-Induced Immune-Mediated Liver Injury: Corticosteroid as a Possible Therapeutic Option. Front Oncol 2020;10:1160. [PMID: 32754445 DOI: 10.3389/fonc.2020.01160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]